Moleculin Biotech (MBRX) shares dropped about 19% in recent Wednesday trading after the company said no patients achieved complete response in the phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma lung metastases, a type of cancer.
The trial, however, demonstrated a clinical benefit rate of 59.4%, primarily comprising 18 cases of stable disease and one partial response, the company said.
The median progression-free survival in the 36 subjects participating in the trial was 63 days, while median overall survival clocked in at 411 days, the company said.
In the phase 2 portion of the study, which was made up of 17 subjects, the median progression-free survival was 105 days, with overall survival coming in at 13.5 months, the company added.
Annamycin holds the US Food and Drug Administration's orphan drug designation for the treatment of soft tissue sarcoma.
Price: 0.68, Change: -0.16, Percent Change: -18.55
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。